OraSure Technologies (NASDAQ:OSUR) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

OraSure Technologies (NASDAQ:OSUR) released its quarterly earnings results on Monday. The medical instruments supplier reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.05, FiscalAI reports. The company had revenue of $30.91 million during the quarter, compared to analysts’ expectations of $31.00 million. OraSure Technologies had a negative net margin of 41.73% and a negative return on equity of 19.55%.

Here are the key takeaways from OraSure Technologies’ conference call:

• Q3 revenue grew 14% year over year to $30.9 million, while gross margin expanded 173 basis points to 45.2% and operating expenses declined. OraSure expects full-year 2026 revenue of $119.5 million to $121.5 million, implying growth of 3.8% to 5.6%.
• Both major portfolios grew, with diagnostics revenue up 16% and sample management solutions up 21% year over year. OraSure cited early Colli-Pee sales and continued demand for U.S. HIV, HCV, and syphilis testing, while saying new products should contribute to faster growth in 2027.
• The company now expects to reach operating cash flow breakeven in the second half of 2027, later than its prior goal of breakeven entering 2027, as the timing and mix of growth opportunities changed.
• Ebola testing commercialization remains dependent on pending study results and evolving country-specific evaluation and procurement processes. OraSure has fulfilled initial orders and expects further contracting before year-end, but did not provide sales estimates or a firm timeline for broader adoption.
• The regulatory path for OraQuick InteliQuick CT/NG remains uncertain after the company withdrew its FDA submission in August. OraSure is in pre-submission discussions to determine a resubmission pathway, with timing and potential costs still unclear.

OraSure Technologies Stock Down 5.7%

OraSure Technologies stock opened at $3.33 on Wednesday. OraSure Technologies has a 12 month low of $2.08 and a 12 month high of $4.58. The stock’s 50 day moving average is $3.72 and its 200-day moving average is $3.54.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of OraSure Technologies in a research report on Tuesday, September 1st. Craig Hallum upgraded shares of OraSure Technologies to a “strong-buy” rating in a research note on Friday, October 23rd. Wall Street Zen upgraded OraSure Technologies from a “sell” rating to a “hold” rating in a report on Monday, August 10th. Finally, Zacks Research raised OraSure Technologies to a “hold” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc. develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows. Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.